The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...

Please provide your email address to receive an email when new articles are posted on . Being male or aged older than 40 years were consistently associated with poorer acute optic neuritis outcomes.

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

The symptoms of MS vary widely in location and severity among individuals. Common symptoms include fatigue, numbness, focal weakness, visual changes such as unilateral visual loss and diplopia, ...

Optic atrophy is a condition in which the optic nerve begins to deteriorate. The optic nerve is the nerve at the back of your eye that connects your eye to your brain, allowing you to see. There are a ...

"Our decision to treat typically needs to be made on the balance of likelihood, before the diagnosis of an associated disease process can be fully established, with definitive tests for multiple ...

Your ability to see the world around you hinges on how well different structures in your eye perform their designated jobs. The optic nerve — actually a bundle of more than one million nerve fibers — ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...